Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma

Kruse, Carol A.; Mitchell, Dawn H.; Kleinschmidt‐DeMasters, Bette K.; Bellgrau, Donald; Eule, James M.; Parra, JosE Roberto Postali; Kong, Qingzhong; Lillehei, Kevin O.

doi:10.1007/bf01053931

Cited by 23 publications

(7 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been extensively used to study chemotherapy and radiation effects (Henderson et al, 1981; Wen et al, 1990; Kimler et al, 1992; Kruse et al, 1993). Recently, it has also been used to study tumour stem cells (Ghods et al, 2007).…”

Section: L Glioma Modelmentioning

confidence: 99%

Current Review of in Vivo GBM Rodent Models: Emphasis on the CNS-1 Tumour Model

Jacobs

Valdés

Hickey³

et al. 2011

ASN Neuro

206

189

View full text Add to dashboard Cite

GBM (glioblastoma multiforme) is a highly aggressive brain tumour with very poor prognosis despite multi-modalities of treatment. Furthermore, recent failure of targeted therapy for these tumours highlights the need of appropriate rodent models for preclinical studies. In this review, we highlight the most commonly used rodent models (U251, U86, GL261, C6, 9L and CNS-1) with a focus on the pathological and genetic similarities to the human disease. We end with a comprehensive review of the CNS-1 rodent model.

show abstract

Section: L Glioma Modelmentioning

confidence: 99%

Current Review of in Vivo GBM Rodent Models: Emphasis on the CNS-1 Tumour Model

Jacobs

Valdés

Hickey³

et al. 2011

ASN Neuro

206

189

View full text Add to dashboard Cite

show abstract

“…Additionally, this model is also likely to be highly informative and useful for testing various augmentation strategies, such as lymphodepleting chemotherapy, which has shown promise as a preconditioning regimen to augment adoptive immunotherapy in experimental models dating back 25 years23–25 as well as in recent clinical trials 26,27…”

Section: Discussionmentioning

confidence: 99%

PTEN Knockout Prostate Cancer as a Model for Experimental Immunotherapy

et al. 2009

Self Cite

View full text Add to dashboard Cite

Purpose-Testing immunotherapeutic strategies for prostate cancer has been impeded by the lack of relevant tumor models in immunocompetent animals. This opportunity is now provided by the recent development of prostate specific PTEN knockout mice, which show spontaneous development of true adenocarcinoma arising from prostate epithelium and more faithfully recapitulate the human disease than any previous model. We investigated the feasibility of using tumor cells derived from this model to test tumor vaccination and adoptive immunotherapeutic strategies for prostate cancer.Materials and Methods-PTEN-CaP8 adenocarcinoma cells derived from the biallelic PTEN knockout prostate cancer model were used to vaccinate nontumor bearing litter mates. Tumor specific effector cells were generated from splenocytes of vaccinated mice by mixed lymphocyte-tumor reactions, and antiproliferative effects and cytokine generation were examined in vitro. The effect of vaccination or adoptive immunotherapy on luciferase marked PTEN-CaP8 subcutaneous tumors was monitored by tumor volumetric measurements and noninvasive bioluminescence imaging.Results-Vaccination of litter mate mice with irradiated PTEN-CaP8 cells showed a significant prophylactic effect against the subsequent tumor challenge. Effector cells harvested from vaccinated litter mates showed significant interferon-γ secretion upon co-incubation with PTEN-CaP8 target cells and they were capable of efficient target cell growth inhibition in vitro. Intratumor adoptive transfer of effector cells resulted in significant growth inhibition of preestablished prostate tumors in vivo.Conclusions-The PTEN knockout model serves as a highly useful model in which to investigate tumor cell vaccination and adoptive immunotherapeutic strategies in the context of true adenocarcinoma of the prostate. This model should accelerate efforts to develop effective immunotherapies for human prostate cancer.

show abstract

“…Presumably, the LAK cells can also kill their target cells MHC independently. Interestingly, synergistic effects of LAK cells and anticancer drugs have been reported [118]. Many clinical studies using LAK cells to treat patients with malignant glioma have been published [88,[119][120][121][122][123][124][125][126].…”

Section: Review Articlementioning

confidence: 98%

Chemotherapy and immunotherapy of malignant glioma: molecular mechanisms and clinical perspectives

Roth¹,

Weller

1999

Cellular and Molecular Life Sciences (CMLS)

View full text Add to dashboard Cite

Despite the considerable progress in modern Immunotherapeutic approaches include cytotoxic cytumor therapy, the prognosis for patients with glioblas-tokines, targeted antibodies, and vaccination strategies. toma, the most frequent malignant brain tumor, has not However, the success of most of these experimental therapies is prevented by the marked molecular resisbeen substantially improved. Although cytoreductive tance of glioma cells to diverse cytotoxic agents or by surgery and radiotherapy are the mainstays of treatglioma-associated immunosuppression. One promising ment for malignant glioma at present, novel cytotoxic drugs and immunotherapeutic approaches hold great experimental strategy to target glioma is the employment of death ligands such as CD95 (Fas/Apo1) ligand promise as effective weapons against these malignancies. Thus, great efforts are being made to enhance or Apo2 ligand (TRAIL). Specific proapoptotic apantitumoral efficacy by combining various cytotoxic proaches may overcome many of the obvious obstacles to a satisfactory management of malignant brain tuagents, by novel routes of drug administration, or by combining anticancer drugs and immune modulators. mors.

show abstract

Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma

Cited by 23 publications

References 38 publications

Current Review of in Vivo GBM Rodent Models: Emphasis on the CNS-1 Tumour Model

Current Review of in Vivo GBM Rodent Models: Emphasis on the CNS-1 Tumour Model

PTEN Knockout Prostate Cancer as a Model for Experimental Immunotherapy

Chemotherapy and immunotherapy of malignant glioma: molecular mechanisms and clinical perspectives

Contact Info

Product

Resources

About